Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2174/092986710792065090 http://scihub22266oqcxt.onion/10.2174/092986710792065090 20858169!ä!20858169 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20858169&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\20858169.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Curr+Med+Chem 2010 ; 17 (26): 2873-81 Nephropedia Template TP {{tp|p=20858169|t=2010. Using small molecule GSK3beta inhibitors to treat inflammation |pdf=|usr=}}{{20858169}} gab.com Text Using small molecule GSK3beta inhibitors to treat inflammation JO: Curr Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=20858169 #FOAvip Glycogen Synthase Kinase 3 beta (GSK3beta) is a serine-threonine kinase originally identified for its role in the conversion of glucose to glycogen. Pharmacological inhibition can be achieved by drug binding to ATP or magnesium binding sites on the enzyme. Pharmaceutical companies have developed several small molecule GSK3beta inhibitors for diabetes research. Additionally, GSK3beta inhibitors are being clinically tested as therapeutics for neurological diseases, however, the mechanisms of involvement are unclear. Several studies have shown that the therapeutic effect of GSK3beta inhibition is associated with the inhibition of inflammation. Similarly, the mechanisms underlying the anti-inflammatory function of GSK3beta inhibition are not well understood. GSK3beta inhibition attenuates activation of the pro-inflammatory transcription factor NFkappaB, and activates the immuno-modulatory transcription factor beta-catenin. GSK3beta inhibition has also been shown to induce secretion of the anti-inflammatory cytokine IL-10. In addition, pharmacological inhibition of GSK3beta suppressed alloreactive T-cell responses. The combined anti-proliferative and anti-inflammatory properties of small molecule inhibitors of GSK3beta make them an attractive treatment modality towards the control of inflammation. Twit Text FOAVip Using small molecule GSK3beta inhibitors to treat inflammation ????Curr Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=20858169 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=20858169 #FOAvip English Wikipedia <ref>{{Cite pmid|20858169}}</ref> Using small molecule GSK3beta inhibitors to treat inflammation #MMPMID20858169 Klamer G; Song E; Ko KH; O'Brien TA; Dolnikov A Curr Med Chem 2010[]; 17 (26): 2873-81 PMID20858169show ga Glycogen Synthase Kinase 3 beta (GSK3beta) is a serine-threonine kinase originally identified for its role in the conversion of glucose to glycogen. Pharmacological inhibition can be achieved by drug binding to ATP or magnesium binding sites on the enzyme. Pharmaceutical companies have developed several small molecule GSK3beta inhibitors for diabetes research. Additionally, GSK3beta inhibitors are being clinically tested as therapeutics for neurological diseases, however, the mechanisms of involvement are unclear. Several studies have shown that the therapeutic effect of GSK3beta inhibition is associated with the inhibition of inflammation. Similarly, the mechanisms underlying the anti-inflammatory function of GSK3beta inhibition are not well understood. GSK3beta inhibition attenuates activation of the pro-inflammatory transcription factor NFkappaB, and activates the immuno-modulatory transcription factor beta-catenin. GSK3beta inhibition has also been shown to induce secretion of the anti-inflammatory cytokine IL-10. In addition, pharmacological inhibition of GSK3beta suppressed alloreactive T-cell responses. The combined anti-proliferative and anti-inflammatory properties of small molecule inhibitors of GSK3beta make them an attractive treatment modality towards the control of inflammation. |Anti-Inflammatory Agents/chemistry/pharmacology/*therapeutic use[MESH] |Glycogen Synthase Kinase 3 beta[MESH] |Glycogen Synthase Kinase 3/*antagonists & inhibitors[MESH] |Humans[MESH] |Inflammation/*drug therapy[MESH] |Signal Transduction/drug effects[MESH] |Wnt Proteins/metabolism[MESH]Using small molecule GSK3beta inhibitors to treat inflammation (epmc).pdf DeepDyve Pubget Overpricing